← Back to headlines
Altimmune a new buy at Truist on pemvidutide promise
Truist initiates coverage on Altimmune with a buy rating, citing the potential of its drug pemvidutide.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.

